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BACKGROUND: Prostate cancer screening with prostate-specific antigen (PSA) has shown to reduce prostate cancer mortality in the
European Randomised study of Screening for Prostate Cancer (ERSPC) trial. Overdetection and overtreatment are substantial
unfavourable side effects with consequent healthcare costs. In this study the effects of introducing widespread PSA screening is
evaluated.
METHODS: The MISCAN model was used to simulate prostate cancer growth and detection in a simulated cohort of 100000 men
(European standard population) over 25 years. PSA screening from age 55 to 70 or 75, with 1, 2 and 4-year-intervals is simulated.
Number of diagnoses, PSA tests, biopsies, treatments, deaths and corresponding costs for 100000 men and for United Kingdom and
United States are compared.
RESULTS: Without screening 2378 men per 100000 were predicted to be diagnosed with prostate cancer compared with 4956 men
after screening at 4-year intervals. By introducing screening, the costs would increase with 100% to h60695000. Overdetection is
related to 39% of total costs (h23669000). Screening until age 75 is relatively most expensive because of the costs of overtreatment.
CONCLUSION: Introduction of PSA screening will increase total healthcare costs for prostate cancer substantially, of which the actual
screening costs will be a small part.
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Prostate cancer is one of the leading causes of cancer deaths in
men. Early detection as a result of screening may result in a
decrease in prostate cancer mortality as shown in the European
Randomised study of Screening for Prostate Cancer (ERSPC) trial
(Schro ¨der et al, 2009). In this European trial, screening with
prostate-specific antigen (PSA) reduced prostate cancer mortality
by at least 20%.
Apart from the effects on mortality and the balance with
unfavourable effects, the decision whether to introduce screening
of prostate cancer will also depend on the expected costs of
screening and treatment. The introduction of PSA screening will
lead to a substantial increase in cancers detected. In the Rotterdam
section of the ERSPC trial, the first round detection rate in the
screened arm (54 cases per 1000 men) was nearly 30 times the
incidence in 1991 without screening (2 cases per 1000) and 17
times the incidence in the control arm (3 cases per 1000) (Draisma
et al, 2003; van der Cruijsen-Koeter et al, 2005). It is expected that
part of the screen-detected prostate tumours (7–56%) might never
give rise to clinical symptoms and might not lead to death caused
by prostate cancer (Zappa et al, 1998; Draisma et al, 2003, 2009;
Telesca et al, 2008). These overdetected, indolent prostate cancers
are an important factor in determining the cost-effectiveness and
desirability of a population-wide screening programme on prostate
cancer. By using a simulation model (Draisma et al, 2003, 2006),
the number of diagnoses, stage distribution and costs can be
predicted for a future period using the screening algorithm as was
done in the ERSPC trial.
The purpose of this study is to predict the costs of diagnosis,
primary treatment of prostate cancer and the costs of over-
detection when screening by PSA testing as done in the ERSPC trial
is introduced population wide and to compare these with the costs
of treatment when no screening is performed.
MATERIALS AND METHODS
Model description
The computer program MISCAN, MIcrosimulation SCreening
ANalysis, was used for the evaluation of prostate cancer screening.
MISCAN is a stochastic package simulating individual life
histories. The MISCAN model reproduces age-specific incidence
of prostate cancer as well as mortality from other causes than
prostate cancer. A more detailed description of the basic MISCAN
model can be found elsewhere (Draisma et al, 2003, 2006). The
model has been updated with more recent data from the ERSPC
trial Rotterdam.
A cohort of 100000 men was used with an age distribution
according to the European Standard Population 2003 (National
Centre for Health Outcomes Development, NCHOD, UK). The
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sprobability that a man will develop prostate cancer is calculated
using the disease and treatment-specific parameters estimated
from the Rotterdam ERSPC trial data.
After invitation a PSA test will be performed. At a PSA level
X3ngml
 1 a lateralised sextant biopsy is recommended. At a
lower PSA level the screened individual will have to come back for
a next screening after 4 years. The biopsy tissue is analysed by a
pathologist. If the outcome is negative the man has to come back
after 4 years. If positive, the individual has prostate cancer and he
will be informed by his general practitioner. After staging, the
individual will undergo primary therapy. Individuals with the
disease in an advanced stadium (metastasis) will undergo palliative
therapy. When primary therapy (radical prostatectomy, radio-
therapy or active surveillance) is pursued the individual will, after
follow-up, either be cured of prostate cancer or enter the advanced
disease stadium and he will receive palliative therapy. It is also
possible that cancer is detected between screening rounds. The
men with interval cancers will follow the same routes after staging.
Model application
Screening was modelled at ages 55–70 years with a 4-year interval
(at ages 55, 59, 63 and 67 years) for the period 2008–2033 and a
hypothetical screening attendance of 100%. Three alternative
screening strategies have been modelled: (1) screening from age 55
to 70 with 1-year intervals (2) screening from age 55 to 70 with
2-year intervals and (3) screening from age 55 to 75 with 4-year
intervals. The outputs of the model were the number of diagnoses
by stage (T, Gleason score and metastasis) and age in the situation
without screening and the number of screen visits, diagnoses by
stage (T, Gleason score and metastasis), age, divided in clinically
diagnosed (interval cancers), relevant (screen-detected cancers
that would have given rise to clinical symptoms later in life) and
overdetected (screen-detected cancers that would never given rise
to clinical symptoms and would not have lead to death caused by
prostate cancer) in the situation with screening (Draisma et al,
2009), all in the period 2008–2033.
To take false positive biopsies into account, the total number of
biopsies of the screen-detected cancers was calculated using the
predicted number of diagnoses and the mean positive predictive
value of 22.3% (Postma et al, 2007) of a biopsy in the screen arm of
the ERSPC trial. For the clinically detected cancers and the
diagnosed cancers in the situation without screening the positive
predictive value of 35.8% (Otto et al, 2003) of a biopsy in the
control arm of the ERSPC trial was used.
The individuals with metastases are treated with palliative
therapy. The individuals without metastases are treated with
radical prostatectomy, radiotherapy or active surveillance. The
distribution of these therapies were determined from the observed
frequencies of the therapies in the screen arm and control arm of
the ERSPC Rotterdam in the period 2000–2006, and were based on
clinical T stage of the tumour, Gleason score and age of diagnosis.
The percentages of men that are cured were estimated by the
10-year relative survival by clinical T stage in 1989–2005 in the
Netherlands. For T1 and T2, a relative survival of 87% was used,
for T3 a relative survival of 77% (source: IKA, Comprehensive
Cancer Centre Amsterdam).
Costs
Direct medical costs were calculated, mainly based on Dutch
sources, for the year 2008. The costs were obtained from literature,
own estimates or tariffs from the Dutch Healthcare Authority 2008
(NZA), the governmental supervisor of healthcare budget in the
Netherlands. Indirect costs are not included. All cost estimates are
calculated in h2008. Corrections for inflation were made if
necessary.
The unit costs of screening, diagnosis, primary therapy, follow-
up and palliative therapy are presented in Table 1. The costs for
invitation of screening, staging and follow-up are estimated, based
on ERSPC data and expected diagnostics. The costs for radical
prostatectomy and radiation therapy are obtained from literature
(Malmberg et al, 1997; Perez et al, 1997; Burkhardt et al, 2002;
Makhlouf et al, 2002) and own hospital data. To estimate the costs
of active surveillance the protocol of the PRIAS study (van den
Bergh et al, 2007) was used: During 7 years, 19 PSA tests, 10 digital
rectal examination (DRE) and 4 biopsies are scheduled. Finally,
the costs of advanced disease were based on chart review
(Beemsterboer et al, 1999). The costs for palliative therapy
consisted of costs for outpatient visit, assessment, treatment
(hormonal, radiotherapy, surgery and other) and hospital days.
To give an indication what the results of this study would mean
for the introduction of widespread PSA screening in a country, the
costs of screening and treatment of prostate cancer were also
calculated for the United Kingdom (30 million men) and the
United States (305 million men). A healthcare-specific purchasing
power parity, including exchange rate, of 0.743 for the United
Kingdom and 1.137 for the United States was applied to the costs
to account for relatively different healthcare costs in those
countries compared with the Netherlands in 2008. The assump-
tions for the incidence and progression of the disease and the
frequency of treatments remained the same.
RESULTS
The differences in number of men diagnosed in the situations
without and with screening (4-year interval until age 70) per
100000 men in 25 years are presented in Table 2. Without
screening, 6642 biopsies are performed and 2378 men are
diagnosed with prostate cancer. Radical prostatectomy and
radiation therapy are the most frequently used treatments (both
30%), followed by active surveillance (18%) and 514 men receive
Table 1 Costs of prostate cancer screening, diagnosis, primary therapy
and advanced disease in Euro (2008)
Intervention Costs Source
Screening 24
Invitation 2 Estimation
Blood sample taking 9.5 NZA
PSA determination 12.5 NZA
Diagnosis 170
Biopsy 92 NZA
PA research 33 NZA
GP consulting 45 20min (tariff per hour h 135.5)
Primary therapy
Staging 200 Estimation
Radical
prostatectomy
11800 Hospital data/literature (Burkhardt et al,
2002; Makhlouf et al, 2002)
Radiotherapy 14178 Literature (Malmberg et al, 1997;
Perez et al, 1997)
Active surveillance 1588 van den Bergh et al (2007)
19 PSA tests 418
10 DRE 490 Estimation h 26 per test and 10min
(tariff per hour h 135.5)
Four biopsies 680
Follow-up 150 Estimation
Advanced disease
Palliative therapy 12276 Literature (Beemsterboer et al, 1999)
Abbreviations: PSA¼prostate-specific antigen; DRE¼digital rectal examination.
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spalliative therapy (22%). After primary treatment, another 241
men receive palliative therapy as well in follow-up.
In the situation with screening, 126888 PSA tests and 19946
biopsies are performed and 4956 men are diagnosed. Of all screen-
detected cancers, 30% are relevant and 42% are overdetected.
Figure 1 shows the stage distribution of the cancers detected in the
situations with and without screening.
Owing to the shift in stage distribution, different treatments are
offered in the screen-detected situation. In total, radiation therapy
(36%) is now the most used treatment, followed by radical
prostatectomy (32%) and active surveillance (26%); however, the
distribution of treatments differs between the clinically detected,
relevant and overdetected cancers. Fewer men (301) receive
palliative therapy than in the situation without screening. Most
of these 301 men, 259 (86%) are clinically detected.
In the situation without screening, the costs for diagnosis and
treatment in 25 years are h 30284000 per 100000 men (Table 3),
consisting of h 1129000 for biopsies and h 29155000 for
treatment. After the introduction of screening, the costs for
diagnosis and treatment increase to h 60695000 (100% increase).
The costs are h 3045000 for screening tests, h 3391000 for
biopsies and h 54259000 for treatment. The costs for palliative
therapy will decrease from h 9374000 to h 7029000, a savings of
25%. In total, only 10% of the additional costs in the screening
situation are attributed to the screening programme itself and
h23669000 (39% of the total costs) can be attributed to
overdetected cancers.
The results of the simulations of the three alternative screening
strategies are shown in Table 4. Screening until age 75 detected the
highest amount of cancers (6981, an increase of 41%, compared
with screening until age 70). The amount of PSA tests increased
with 29% to 163545 and the number of biopsies with 50% to
29954. Screening with a 1-year or a 2-year interval resulted in
453740 (þ258%) and 243387 (þ92%) PSA tests, 24488 (þ23%)
and 23759 (þ19%) biopsies and a smaller increase in numbers of
cancer detected of 5850 (þ18%) and 5709 (þ15%), respectively.
Screening until age 75 resulted in the highest percentage of
overdetected cancers (57%, which equals 3961 cancers). Both other
strategies resulted in 49 and 48% overdetection (Figure 2).
All three alternative scenarios result in higher costs. Two-year
interval screening is the less expensive scenario (70 million Euro),
followed by 1-year interval screening (76 million Euro). Although
the screening costs are lowest for the 4-year interval screening
until age 75, the costs for treatment of overdetected cancers are
much higher, resulting in increased total costs of 83 million Euro.
When screening (4-year interval until age 70) is introduced in
the Unite Kingdom, about 800000 extra cancers will be detected in
25 years, of which 630000 will be overdetected. The costs for
screening, diagnosis and treatment will be about 13.5 billion pound
compared with 6.5 in the situation without screening. For the
United States about 8 million extra cancers will be diagnosed, of
which 6.4 million will be overdetected. The costs for screening,
diagnosis and treatment will be 210 billion US dollars compared
with 105 in the situation without screening.
DISCUSSION
PSA screening for prostate cancer has long been controversial.
Although the PSA test is simple, safe and has an acceptable
sensitivity and specificity, estimates of the costs, risk of over-
diagnosis and side effects of unnecessary treatment are unfavour-
able. In our simulation, in the period 2008–2033, 2578 men extra
per 100000 men will be diagnosed with prostate cancer of which an
estimated number of 2102 men will be overdiagnosed, accounting
for 39% of the total costs for screening and treatment. Therefore,
introduction of PSA population screening for prostate cancer for
men aged 55–67 with 4-year intervals will increase the total costs
of prostate cancer in the next 25 years significantly. The actual
screening costs will only be a small part of the increase (10%). A
shorter screen interval results in more cancers detected, more
overdiagnosis and higher costs. Extended screening to age 75
results in even more cancers detected, more overdiagnosis and
more costs. As the life years gained will probably be less for the
older ages, it seems more appropriate to shorten the screen
Table 2 Number of prostate-specific antigen (PSA) tests, prostate cancer diagnoses and treatments of a cohort of 100000 European Standard men of all
ages in the period 2008–2033
Screening
No screening Total Clinical
a Relevant
a Overdetected
a
PSA tests 0 126888 23919 (19%) 43014 (34%) 59955 (47%)
Biopsies 6642 19946 3760 (19%) 6761 (34%) 9424 (47%)
Cancers detected 2378 4956 1346 (27%) 1508 (30%) 2102 (42%)
Active surveillance 438 1310 266 (20%) 388 (30%) 656 (50%)
Radical prostatectomy 716 1559 410 (26%) 499 (32%) 651 (42%)
Radiation therapy 708 1786 412 (23%) 579 (32%) 795 (45%)
Palliative therapy 514 301 259 (86%) 42 (14%) 0 (0%)
Palliative therapy after primary treatment 241 267 133 (50%) 134 (50%) 0 (0%)
The screening attendance is 100% for the ages 55–70 with a 4-year interval.
aCancers detected in the situation with screening are divided in clinically detected cancers (interval
cancers), relevant cancers (screen-detected cancers that would have given rise to clinical symptoms later in life) and overdetected cancers (screen-detected cancers that would
never given rise to clinical symptoms and would not lead to death caused by prostate cancer).
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Figure 1 The number and stage distribution of cancers per 100000 men
in the next 25 years, in the situation without screening and the situation
with screening (divided in clinically detected cancers, relevant cancers
and overdetected cancers). The screening attendance is 100% for the
ages 55–70 with a 4-year interval. In each column, the cancers are divided
in stage T1, T2, T3 and metastasis (M1).
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sinterval than to extend screening to age 75. However, quality of life
and cost-effectiveness should also be taken into account.
The percentages of overdetected cancers found in this study,
42% and 57%, are comparable to what has been found earlier:
44–56% (Zappa et al, 1998; Draisma et al, 2003, 2009; Telesca et al,
2008). Telesca et al (2008) found lower percentages of 7–32%,
depending on age and race, for the population of the United States.
However, they used a higher PSA threshold for biopsy and a lower
biopsy compliance. The risk of overdiagnosis is higher for
prostate cancer as compared to other types of cancer, because
prostate cancer shows a particularly high prevalence of latent
lesions and because of the high age, the risk of death from
other causes is higher (Zappa et al, 1998). In addition, quality of
life aspects are not included. It was shown that even 5–10 years
after the treatment, 23–48% of the prostate cancer survivors
have urinary problems, 5–14% has bowel problems and 40–74%
has sexual problems (Mols et al, 2009). These percentages
were significantly higher than found in the age-matched
normative population. Especially the overdetected cases will
experience the negative consequences, without the benefits of
screening.
There are few recent cost-effectiveness studies for PSA screening
and results are ambiguous (Crawford and Abrahamsson, 2008).
Less recent studies should be used with caution, because of
changing treatments and changing incidence and mortality rates.
In an overview of cost-effectiveness studies of prostate cancer
screening, it was argued that the sensitivity, specificity and positive
predictive value of the PSA test are acceptable (Crawford and
Abrahamsson, 2008).
A hospital in the United Kingdom has measured the costs of the
extra patients, referred to the hospital as a result of PSA screening
by a recruitment company (Chelladurai et al, 2008). In 1 year, 80
additional patients at the costs of 250000 d (about h 4000 per
patient) were treated. The authors state that these costs are likely
to be an underestimation, because costs for further follow-up
and treatment after 1 year have not been considered. In our study,
the costs per additional patient detected would be about h 9000
in 1 year.
Several assumptions had to be made in the simulations. Most of
the disease-specific parameters in the model have been fit to data
of the ERSPC Rotterdam. The predicted clinical T stage of the
tumours in the situation without screening compared well with the
Table 3 Total costs of screening (ages 55–70 with a 4-year interval) and treatment of a cohort of 100000 men of all ages in the period 2008–2033 in
kEuro (2008)
Screening
No screening Total Clinical
a Relevant
a Overdetected
a
PSA tests 0 3045 574 (19%) 1032 (34%) 1439 (47%)
Biopsies 1129 3391 639 (19%) 1149 (34%) 1602 (47%)
Active surveillance 784 2342 475 (20%) 694 (30%) 1173 (50%)
Radical prostatectomy 8704 18947 4976 (26%) 6066 (32%) 7906 (42%)
Radiation therapy 10293 25942 5987 (23%) 8405 (32%) 11550 (45%)
Palliative therapy 6417 3751 3227 (86%) 524 (14%) 0 (0%)
Palliative therapy after primary treatment 2957 3277 1634 (50%) 1643 (50%) 0 (0%)
Total costs 30284 60695 17512 (29%) 19513 (32%) 23669 (39%)
Abbreviation: PSA¼prostate-specific antigen.
aCancers detected in the situation with screening are divided in clinically detected cancers (interval cancers), relevant cancers
(screen-detected cancers that would have given rise to clinical symptoms later in life) and overdetected cancers (screen-detected cancers that would never given rise to clinical
symptoms and would not lead to death caused by prostate cancer).
Table 4 Number of PSA tests, prostate cancer diagnoses and
treatments and costs (in kEuro 2008) of a cohort of 100000 men of all
ages in the period 2008–2033
55–70,
1 year
55–70,
2 year
55–75,
4 year
PSA tests 453740 243387 163545
Biopsies 24488 23759 29954
Cancers detected 5850 5709 6981
Active surveillance 1714 1614 1942
Radical prostatectomy 1792 1779 2214
Radiation therapy 2099 2065 2608
Palliative therapy 245 251 217
Palliative therapy after primary
treatment
218 246 277
Costs screening (kEuro) 10890 (14%) 5841 (8%) 3925 (5%)
Costs biopsies and treatment
Clinical 13032 (17%) 13695 (19%) 9889 (12%)
Relevant 22758 (30%) 22476 (32%) 27412 (33%)
Overdetected 29446 (39%) 28524 (40%) 42165 (51%)
Total costs (kEuro) 76126 70536 83391
Abbreviation: PSA¼prostate-specific antigen. Three screening scenarios are shown:
screening for the ages 55–70 with a 1-year interval and a 2-year interval and
screening for the ages 55–75 with a 4-year interval. The attendance is 100% in all
scenarios.
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Figure 2 Number of cancers detected per 100000 men in 25 years for
three screening scenarios (1-year interval ages 55–70: int1, 2-year interval
ages 55–70: int2, 4-year interval ages 55–75: to75) for clinically detected
cancers (interval cancers), relevant cancers (screen-detected cancers that
would have given rise to clinical symptoms later in life) and overdetected
cancers (screen-detected cancers that would never given rise to clinical
symptoms and would not lead to death caused by prostate cancer).
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sobserved distribution in a part of the Netherlands in 1999–2001:
T1 and T2: 62%; T3: 16%; T4: 22% in the simulation, compared
with 56%, 21% and 22%, respectively, in the Netherlands (Visser
and van Leeuwen, 2005). The treatments the diagnosed men
received in our simulation were also based on the observed
treatments in the ERSPC trial. These treatments can differ in the
future. When active surveillance will be applied for more patients,
the total treatment costs will be lower, whereas an increase in, for
example, hormonal treatment or brachytherapy will increase the
total costs. Recently, two nomograms have been validated that can
help in the prediction of indolent cancers, and therefore reduce the
number of overtreated cancers (Dong et al, 2008). Measures of
uncertainty in the results are difficult to obtain, because there are
many parameters in the model. Changes in natural history of the
tumors would have an influence on the proportion of over-
diagnosis. In the publication of Draisma et al (2003), the 95%
confidence interval for proportion of overdetection was 46–57%,
which means that despite the uncertainty, the costs for over-
detection are always substantial.
In the model the effects of screening with 100% attendance is
compared with a situation without screening. However, in most
European countries, screening is already going on and when
screening will be implemented less than 100% of men invited will
participate. In the ERSPC Rotterdam section, it was estimated that
15% of the men in the control arm did have at least one PSA test
for screening purposes (Roobol et al, 2009). As the population who
attends opportunistic screening is not comparable with the general
population (the ‘healthy screenee’ effect), we have chosen to
compare all strategies with a situation of no screening at all. In
addition, the attendance rate will not be 100% when screening is
implemented. Comparing the strategy screening at ages 55–70
with 4-year intervals with an attendance of 80% with a background
screening of 15% results in overdiagnosis of 1252 men. The total
costs for the situation with 15% screening are 38 million Euro and
with 80% screening 57 million Euro and therefore the increase in
costs after implementing screening will be 50%.
A limitation of this study is that indirect costs (administrative
costs, patient’s loss of income from time off from work, travelling
costs and time, costs of complications resulting from biopsy or
treatment) are not included. Therefore, it is expected that the
actual total costs of prostate cancer in a situation with screening
will be higher than predicted in this study. However, even without
these additional costs, the costs of overdetection are already
substantial.
The costs for PSA test, DRE, TRUS and biopsy used in this study
are comparable with the costs mentioned in a literature overview
(Ekwueme et al, 2007). The pooled baseline resource costs
extracted from 13 studies in Canada, Sweden, United Kingdom,
Australia and Japan, calculated in US $ 2003 were $ 30.9 for PSA
test, $ 33.5 for DRE, $ 103.8 for TRUS and $ 165 for biopsy (in 2008
h these costs would be: h 28.7, h 31.1, h 96.2 and h 152.3,
respectively). These costs are comparable with the costs used in
our study. In addition, the total predicted costs for prostate cancer
without screening are comparable with the actual costs in the
Netherlands. The costs of 30 million Euro per 100000 men in 25
years can be recalculated as 96 million Euro per 8 million (all men
in the Netherlands) per year. In 2005, the actual costs for prostate
cancer in the Netherlands were 101.6 million Euro (Poos et al,
2008).
In conclusion, the implementation of PSA screening for
prostate cancer will lead to a doubling of the total costs for
prostate cancer. Only a small part of this increase can be attributed
to the costs of screening itself. Most of the additional costs are for
diagnosis and treatment, especially for overdiagnosed cases.
Prevention of overdiagnosis and overtreatment, quality of life
and cost-effectiveness should be considered in the discussion
whether it is desirable to introduce widespread screening of
prostate cancer.
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